What major regulatory milestone did Firebrick Pharma (ASX:FRE) reach in Canada?

Firebrick Pharma (ASX:FRE) received patent acceptance from the Canadian Intellectual Property Office for its Nasodine Nasal Spray.

How does this new Nasodine patent differ from Firebrick Pharma’s previous Canadian approvals?

While the company’s first Canadian patent focused on treating the common cold, this new approval targets "highly pathogenic viruses." It specifically protects the use of Nasodine to reduce the viral load and shedding of COVID-19 in the nasal passages.

Does the Canadian patent for Firebrick Pharma (ASX:FRE) cover prevention or just treatment?

The patent claims extend to "pre-exposure prophylaxis," meaning it covers Nasodine's use as a preventative measure before a person is exposed to the virus. This provides a dual-use narrative for the product as both a treatment to reduce viral shedding and a preventative tool.

How long is the patent protection for Nasodine in the Canadian market?

The newly accepted patent is set to remain in effect until 2040. This provides Firebrick Pharma with a 14-year commercial runway in Canada, protecting its intellectual property and market exclusivity for nearly two decades.

Is Firebrick Pharma (ASX:FRE) pursuing similar intellectual property protection in other global markets?

Yes, the Canadian acceptance follows a broader international strategy. Firebrick Pharma has already secured or seen acceptance for similar patents in the United States, Europe, and Australia, indicating a consistent global rollout of its intellectual property.

What is the current market valuation of Firebrick Pharma (ASX:FRE) following this news?

At the time of the announcement, Firebrick Pharma’s share price was $0.045. As a micro-cap stock at this price point, the company remains in a highly speculative bracket, though the patent provides a clearer legal framework for future commercialization.

Firebrick Pharma secures key Nasodine patent in Canada

Written by Mahathir BayenaPublished May. 13 2026Last Updated May. 13 2026

Firebrick Pharma (ASX:FRE) has achieved a regulatory milestone in North America with the Canadian Intellectual Property Office accepting a critical new patent for its flagship product, Nasodine Nasal Spray.

This marks the second Nasodine-related patent granted in Canada, following an earlier approval focused on the common cold.

The newly accepted patent, titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes", specifically protects the use of povidone-iodine preparations to reduce the viral load and shedding of SARS-CoV-2 within the nasal passages.

Beyond immediate treatment, the granted claims notably extend to pre-exposure prophylaxis, offering a preventative layer for individuals before they are exposed to the virus.

The intellectual property protection is set to remain in effect until 2040, securing Firebrick Pharma's commercial runway in the region for nearly two decades.

The Canadian acceptance mirrors a broader international trend for the company; similar patents have already been granted or accepted in the United States, Europe, and Australia.

At the time of reporting, Firebrick Pharma’s share price was $0.045.